A detailed history of Cetera Investment Advisers transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Cetera Investment Advisers holds 217,702 shares of GILD stock, worth $20 Million. This represents 0.04% of its overall portfolio holdings.

Number of Shares
217,702
Previous 213,901 1.78%
Holding current value
$20 Million
Previous $15.7 Million 4.67%
% of portfolio
0.04%
Previous 0.04%

Shares

27 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 22, 2024

BUY
$63.15 - $72.88 $240,033 - $277,016
3,801 Added 1.78%
217,702 $14.9 Million
Q1 2024

May 24, 2024

BUY
$71.58 - $87.29 $12.4 Million - $15.1 Million
173,158 Added 425.0%
213,901 $15.7 Million
Q1 2024

May 14, 2024

SELL
$71.58 - $87.29 $3.81 Million - $4.65 Million
-53,249 Reduced 56.65%
40,743 $2.98 Million
Q4 2023

Feb 13, 2024

BUY
$73.27 - $83.09 $470,686 - $533,770
6,424 Added 7.34%
93,992 $7.61 Million
Q3 2023

Nov 14, 2023

SELL
$73.94 - $80.67 $234,020 - $255,320
-3,165 Reduced 3.49%
87,568 $6.56 Million
Q2 2023

Aug 09, 2023

SELL
$76.01 - $86.7 $516,639 - $589,299
-6,797 Reduced 6.97%
90,733 $6.99 Million
Q1 2023

May 15, 2023

SELL
$77.31 - $88.08 $267,801 - $305,109
-3,464 Reduced 3.43%
97,530 $8.09 Million
Q4 2022

Feb 14, 2023

BUY
$62.32 - $89.47 $2.39 Million - $3.42 Million
38,276 Added 61.03%
100,994 $8.67 Million
Q3 2022

Nov 10, 2022

SELL
$59.54 - $68.01 $259,832 - $296,795
-4,364 Reduced 6.51%
62,718 $3.87 Million
Q2 2022

Aug 11, 2022

BUY
$57.72 - $65.01 $526,117 - $592,566
9,115 Added 15.72%
67,082 $4.15 Million
Q1 2022

May 13, 2022

BUY
$57.92 - $72.58 $282,475 - $353,972
4,877 Added 9.19%
57,967 $3.45 Million
Q4 2021

Feb 14, 2022

SELL
$64.88 - $73.64 $1.29 Million - $1.46 Million
-19,828 Reduced 27.19%
53,090 $3.86 Million
Q3 2021

Nov 16, 2021

SELL
$67.69 - $73.03 $115,749 - $124,881
-1,710 Reduced 2.29%
72,918 $5.09 Million
Q2 2021

Aug 13, 2021

BUY
$63.47 - $69.35 $874,807 - $955,851
13,783 Added 22.65%
74,628 $5.14 Million
Q1 2021

May 17, 2021

SELL
$60.0 - $68.46 $1.12 Million - $1.27 Million
-18,612 Reduced 23.42%
60,845 $3.93 Million
Q4 2020

Feb 17, 2021

BUY
$56.65 - $64.55 $4.23 Million - $4.82 Million
74,634 Added 1547.46%
79,457 $4.63 Million
Q3 2020

Nov 13, 2020

SELL
$62.1 - $78.08 $36,328 - $45,676
-585 Reduced 10.82%
4,823 $305,000
Q2 2020

Aug 13, 2020

SELL
$72.34 - $84.0 $579,081 - $672,420
-8,005 Reduced 59.68%
5,408 $416,000
Q1 2020

May 08, 2020

BUY
$62.63 - $80.22 $840,056 - $1.08 Million
13,413 New
13,413 $1 Million
Q4 2018

Feb 15, 2019

SELL
$60.54 - $79.0 $301,731 - $393,736
-4,984 Closed
0 $0
Q3 2018

Nov 14, 2018

BUY
$71.28 - $78.92 $10,620 - $11,759
149 Added 3.08%
4,984 $389,000
Q2 2018

Aug 14, 2018

SELL
$64.88 - $75.68 $244,402 - $285,086
-3,767 Reduced 43.79%
4,835 $342,000
Q1 2018

May 09, 2018

SELL
$72.84 - $88.8 $6,191 - $7,548
-85 Reduced 0.98%
8,602 $655,000
Q4 2017

Feb 08, 2018

SELL
$71.15 - $83.52 $106,511 - $125,029
-1,497 Reduced 14.7%
8,687 $621,000
Q3 2017

Nov 16, 2017

SELL
$72.11 - $85.47 $73,768 - $87,435
-1,023 Reduced 9.13%
10,184 $822,000
Q2 2017

Aug 17, 2017

SELL
N/A
-54,092 Reduced 82.84%
11,207 $792,000
Q2 2017

Aug 14, 2017

BUY
N/A
65,299
65,299 $4.62 Million

Others Institutions Holding GILD

About GILEAD SCIENCES, INC.


  • Ticker GILD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,253,369,984
  • Market Cap $115B
  • Description
  • Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...
More about GILD
Track This Portfolio

Track Cetera Investment Advisers Portfolio

Follow Cetera Investment Advisers and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cetera Investment Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Cetera Investment Advisers with notifications on news.